| Methods |
Five‐week randomised, double‐blind study |
| Participants |
Inpatients fulfilling DSM‐III‐R criteria for major depressive disorder, with a score of at least 18 on the first 17 items of Hamilton Rating Scale for Depression‐17 item (HDRS‐17).
Mean age: 48 years
Exclusion criteria: not stated |
| Interventions |
Fluoxetine: 15 participants
Clomipramine: 15 participants
Fluoxetine dose: 20 mg/day
Clomipramine dose: 75 mg/day |
| Outcomes |
HDRS, Montgomery and Asberg Scale for Depression (MADRS), Clinical Global Impression (CGI), Zung Self‐Rating for Depression |
| Notes |
Funding: unclear |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Randomised, no further information |
| Allocation concealment (selection bias) |
Unclear risk |
No information provided |
| Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
Double blind, no further information |
| Blinding of participants and personnel (performance bias)
All outcomes |
Unclear risk |
Double blind, no further information |
| Blinding of outcome assessment (detection bias)
All outcomes |
Unclear risk |
Double blind, no further information |
| Incomplete outcome data (attrition bias)
All outcomes |
High risk |
Number and reasons for dropout not reported. Scores reported without denominators |
| Selective reporting (reporting bias) |
High risk |
Endpoint scores were reported only in figures and they were not clear. Side effects reported only in percentage without denominators |
| Other bias |
Unclear risk |
Funding: unclear |
